Patents by Inventor Wilda Laux

Wilda Laux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 11390870
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: July 19, 2022
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF
    Publication number: 20210079396
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Application
    Filed: September 25, 2020
    Publication date: March 18, 2021
    Inventors: Wilda LAUX, Colin Richard GREEN
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 10787667
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: September 29, 2020
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF
    Publication number: 20200063136
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Application
    Filed: November 11, 2019
    Publication date: February 27, 2020
    Inventors: Wilda LAUX, Colin Richard GREEN
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 10472632
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: November 12, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF
    Publication number: 20190194657
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Application
    Filed: January 7, 2019
    Publication date: June 27, 2019
    Inventors: Wilda LAUX, Colin Richard Green
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 10174316
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 8, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF
    Publication number: 20140371297
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Application
    Filed: August 25, 2014
    Publication date: December 18, 2014
    Inventors: Wilda LAUX, Colin Richard GREEN
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 8815819
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: August 26, 2014
    Assignee: Coda Therapeutics, Inc.
    Inventors: Wilda Laux, Colin Richard Green
  • ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF
    Publication number: 20120093768
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Application
    Filed: September 12, 2011
    Publication date: April 19, 2012
    Inventors: WILDA LAUX, Colin Green
  • Antisense compounds targeted to connexins and methods of use thereof
    Patent number: 8034789
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: October 11, 2011
    Assignee: CoDa Therapeutics, Inc.
    Inventors: Wilda Laux, Colin Green
  • Antisense Compounds Targeted to Connexins and Methods of Use Thereof
    Publication number: 20070244062
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Application
    Filed: December 3, 2004
    Publication date: October 18, 2007
    Inventors: Wilda Laux, Colin Green